Approval · Notice of Compliance 217 · 2002
XATRAL: Notice of Compliance 217
Issued February 21, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 217
- Date
- February 21, 2002
- Company
- Sanofi-Synthelabo Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Symptomatic treatment of benign prostatic hyperplasia (bph)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XATRAL | 02245565 | Marketed |
Medicinal ingredients
- ALFUZOSIN HCL 10 MG per TAB